As concerns over European feedstock prices grow amid the fallout from war in the Middle East, the burning question is whether sponsors will continue to reshape the chemicals industry as they have over the past year.

The wave of private equity investment across Europe’s embattled sector names has shaken up an industry traditionally moulded by strategic players, dealmakers say.

Storied incumbents are busy purging portfolios, divesting non-core, specialised and unloved assets in a bid to bolster balance sheets amid a maelstrom of headwinds, including crippling energy costs, depressed sales, overcapacity and low-cost competition from Asia.

Crude oil price hikes over the past week only exacerbate these pressures.

Such conditions create consolidation opportunities for mainstream sponsors and value-oriented turnaround firms alike – but it’s a high-risk play given the struggling sector faces “extinction”, if INEOS founder Sir Jim Ratcliffe is to be believed.

“European chemicals majors with decades of heritage are in some cases being replaced as shareholders by established, as well as emerging, financial investors. These are players we’ve never seen in the space before […] the chemicals landscape is changing dramatically,” according to Edward Middleton, director at etasca, an energy and chemicals advisory firm.

Private equity buyouts of European chemicals assets surged to EUR 12bn in 2025 from EUR 2.6bn in 2024, the highest volume since 2021. Sponsors outpaced strategics as trade-led deals plummeted to EUR 8.5bn last year from EUR 22.7bn in 2024, Mergermarket data revealed.

Deal volumes were buoyed by Carlyle and Qatar Investment Authority’s EUR 7.7bn acquisition of BASF’s Coatings division carve-out in October 2025.

Dutch-Swiss major dsm-firmenich’s proposed sale of its Animal Nutrition & Health (ANH) division to CVC in a EUR 2.2bn deal, announced in January, hints at more to come this year. This anchors European chemicals asset buyouts of EUR 2.7bn so far in 2026, versus sluggish strategic-focussed deal volume down at EUR 466m over the same period, data shows.

“The change is happening across the value chain, from global integrated oil and gas companies to diversified and specialty chemicals players. What unifies the picture is increased sponsor interest,” Middleton said.

Still, there is clear bifurcation in what financial buyers are looking for. While large-cap sponsors jostle for assets in resilient segments like healthcare and CASE (coatings, adhesives and sealants), a growing number of special situations funds are buying up legacy assets producing commoditised products being carved out by global oil and gas majors.

Saudi Aramco-owned chemicals producer SABIC announced last month it had agreed to sell its European petrochemicals business to German special situations fund AEQUITA, and its Engineering Thermoplastics business to Munich-based Mutares, for a combined enterprise value (EV) of USD 950m.

The private equity-dominated bidder pool for SABIC’s petrochems assets included US investor Flacks Group and Klesch, a European industrials-focused holding with a sponsor-like approach. Klesch is also reportedly in talks to acquire BP’s Gelsenkirchen refining facility in Germany.

Value investors seeking bargain bulk chemical deals are certainly spoilt for choice.

A growing number of energy giants including Shell and ExxonMobil are initiating strategic reviews of flagging European facilities. A recent report from industry body Cefic says closures of European chemicals plants have surged six-fold since 2022.

Sector pressures are generating a promising pipeline of downstream carve-outs, including Belgian specialty chemicals company Solvay’s expected fluorine division sale and US-listed Ingevity’s auction of its UK-based Advanced Polymer Technologies unit.

The bidder pool for Ingevity’s APT division is populated by special situations funds including Aurelius, Belgian firm Syntagma and US sponsors OpenGate Capital and Pacific Avenue as the auction enters its second round, as reported by this news service.

Meanwhile, INEOS is reportedly considering selling off parts of its business vinyls business Inovyn, engaging in early-stake talks with suitors for the PVC business in a bid to cut costs and reduce its debt pile.

Consolidation or zombification?

While it appears to be something of a buyer’s market for these assets, it’s worth exploring sponsor appetite for seemingly bottom-of-the-barrel commodities assets with dim growth prospects. What is the end game, and how will it affect the wider sector?

The rationale is two-fold, according to Middleton. “Part of the investment hypothesis is the expectation of an improvement in the cycle, with sponsors running the assets as leanly as possible in the meantime.” Buyers could also look to build a platform for consolidation of similar assets, he said.

AEQUITA’s recent activity in the space supports this thesis.

Its acquisition of SABIC’s petrochems facilities was not its first foray into base chemicals. Last June, AEQUITA announced it was in exclusive discussions to acquire US chemicals giant LyondellBasell’s European olefins and polyolefins assets. AEQUITA’s managing partner has said the businesses are “highly synergistic.”

“The key question is whether these buyers build out a group of unwanted, unloved assets,” Thomas Aertssen, senior manager at PwC said.

Do they cohere as a convincing platform, or simply aggregate woes?

In targeting the former, investors are – somewhat ironically given his recent negative soothsaying – emulating Ratcliffe’s early strategy in building INEOS.

Upon founding INEOS in 1998, Ratcliffe engaged in a decade-long, debt-funded acquisition spree, building out a platform of unloved commodity assets from a host of energy and chemicals majors including BP, ICI, and BASF.

Of course, Ratcliffe’s current foretelling of doom has a purpose – to unlock government support for the European chemicals sector. And progress here could aid those copying his playbook.

Indeed, reports that the European Commission (EC) is exploring a potential easing of European Union (EU) carbon allowances regulations sparked a rally in continental chemicals share prices, unwound only following joint US-Israeli military strikes on Iran.

The EC is also proposing a series of anti-dumping duties that could soften the impact of cheap exports from China flooding the market.

It seems clear European governments, within the EU and outside, will need to continue looking for ways to back chemicals players operating within their borders if they hope to maintain strategic autonomy and industrial resilience.

Sponsors may be making that bet, but this is unlikely to boost long-term growth prospects according to one chemical analyst. “It’s a nice to have, not a game changer,” he said. “My gut feeling is that we go into a zombified sector, populated by low-growth and unproductive assets.”

Even if regulations do ease headwinds, buyers are still making a bold call in anticipating a sector rebound. Though oil has pared gains today (9 March), crude flirting with USD 120bbl earlier in the session is an unwelcome reminder these pressures can always get worse.

“This downcycle is fundamentally different. Previous cycles were driven by a sudden drop in demand that picked up relatively quickly, but the industry is facing much deeper structural issues this time around,” according to Aertssen.

One thing seems clear – corporate carve-outs will continue to shape M&A across the chemicals landscape.

“Players across the value chain are likely to make further divestments. There will be more of the same to come, significantly changing the shareholder and operator base of European chemicals,” Middleton said.